Allos Therapeutics (ALTH) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-11.32M
Depreciation and amortization	220K
Stock-based compensation expense	2.9M
Amortization of intangible asset	113K
Other
Accounts receivable	5.57M
Prepaid expenses and other assets	-218K
Interest receivable on investments
Inventory	-351K
Trade accounts payable	1.78M
Accrued liabilities	-1.99M
Deferred revenue
Net cash provided by (used in) operating activities	-4.27M
Acquisition of property and equipment	-3K
Purchases of investments
Proceeds from maturities of investments	10.3M
Net cash provided by (used in) investing activities	10.3M
Proceeds from issuance of common stock associated with stock options and employee stock purchase plan	0
Proceeds from issuance of common stock, net of issuance costs
Net cash provided by financing activities	0
Net increase (decrease) in cash and cash equivalents	6.03M
Cash and cash equivalents, beginning of period	87.37M
Cash and cash equivalents, end of period	93.4M
Deferred revenue in accounts receivable
Assets recorded for which payment has not yet occurred

Entities mentioned with ALTH

View All Entities